Long Chain Fatty acid Oxidation Disorder (LC-FAOD) Study

A clinical trial in long-chain fatty acid oxidation disorders (LC-FAOD) is looking for participants.

The goal of this 18-month trial will be to study the safety and efficacy of the investigational product UX007 (Triheptanoin or C7) on people who experience persistent symptoms of rhabdomyolysis, hypoglycemia, or cardiomyopathy related to LC-FAOD.

To be eligible for this trial, participants must:
- Be 6 months to 35 years old
- Have a confirmed diagnosis of VLCAD, LCHAD, CPT 2, or TFP
- Experience persistent symptoms of rhabdomyolysis, hypoglycemia, or cardiomyopathy related to LC-FAOD
- Be willing to travel to a clinical site approximately every 4-6 weeks for the first 6 months of the study, and every 12-18 weeks for remaining 12 months

Participants will be REIMBURSED for all travel and study related expenses.
To find out more about the study and to see whether you or your family member might be eligible to participate, please contact:

Elizabeth A. McCracken
Clinical Research Coordinator
Children's Hospital of Pittsburgh of UPMC
412.692.5662
Elizabeth.Mccracken@chp.edu

Additional information can be found on the National Institutes of Health's "Clinical Trials" site.